1 / 10

Diabetes Mellitus 101 for Cardiologists (and Alike): 2015

Explore the aggressive therapeutic strategies using anti-diabetes medications to reduce cardiovascular risk in cardiometabolic patients with type 2 diabetes. Discover the impact of hyperglycemia on complications and mortality, emphasizing early detection, treatment, and continuous monitoring strategies.

danielprice
Download Presentation

Diabetes Mellitus 101 for Cardiologists (and Alike): 2015

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 An Aggressive Pathophysiologic Approach to Therapy of Type 2 Diabetes in Cardiometabolic Patients: The Role of Anti-Diabetes Medications in Reducing CV Risk and Outcomes in Patients with Diabetes: Diabetes Medications May be a Cardiologist’s Best Friend Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor of Medicine, U of Pa. 6105472000

  2. Natural History of ALLDM Age 0-15 15-40+ 15-50+ 25-70+ Macrovascular Complications Disability IR Phenotype MICVAAmp IGT ALL DM DEATH BlindnessAmputationCRF EyeNerveKidney ETOHBPSmoking Disability Microvascular Complications Risk of Dev. Complications

  3. Type2 diabetesisincreasinglyprevalent • Globally, 387 million people • • are living with diabetes1 At least 68% of people >65 years with diabetes die of heart disease2 Mortality risk associated with diabetes(n=820,900)3 3 Hazardratio(95%CI) (diabetesvsnodiabetes) 2 1 0 This will rise to 592 million by 20351 All-cause mortality CVdeath 1. IDF Diabetes Atlas 6th Edition 2014 http://www.idf.org/diabetesatlas; 2. Centers for Disease Control and Prevention 2011; 3. Seshasai et al. N Engl J Med 2011;364:829-41

  4. Hyperglycemia Leads to Complications: May Be Present Prior to Diagnosis Hyperglycemia Spike (+variability) Argument for Early Discovery Pre-diabetes, Early Treatment, Determine on Hospital Admission Continuous PPG A1C Chronic toxicity Acute toxicity Tissue lesion Diabetic complications Microvascular Macrovascular Nephropathy MI Stroke Retinopathy Neuropathy PVD American Diabetes Association. At: http://www.diabetes.org/diabetes-statistics/complications.jsp. Brownlee M. Diabetes mellitus: theory and practice. Elsevier Science Publishing Co., Inc; 1990:279-291. Ceriello A. Diabetes. 2005;54:1-7. 4

  5. Diabetes is associated with significant loss of life years Men Women 7 7 Non-vascular deaths Vascular deaths 6 6 Starts with inc. PPG 5 5 Yearsof lifelost 4 4 3 3 2 2 1 1 0 0 040 50 60 70 Age (years) 80 90 040 50 60 70 Age (years) 80 90 On average, a 50-year-old individual with diabetes and no history of vascular disease will die 6 years earlier compared to someone without diabetes . Seshasaiet al. N EnglJ Med2011;364:829-41

  6. Cardiovascular disease and diabetes No A1C threshold is apparent Finnish study by Kuusisto et al; UKPDS epidemiologic analysis; EPIC-Norfolk Study ~65% of deaths are due to CV disease Cardiovascular complications of T2DM Coronary heart disease deaths2- to 4-fold Stroke risk 2- to 4-fold Impaired glucose tolerance (IGT) and postprandial hyperglycemia are CV risk factors Funagata Diabetes Study; Honolulu Heart Program; DECODE Study; Rancho Bernardo Study Heart failure 2- to 5-fold Bell DSH. Diabetes Care. 2003;26:2433-41. Centers for Disease Control (CDC). www.cdc.gov. T2DM = type 2 diabetes mellitus

  7. Early Treatment Decreases Micro and Macro Vascular RISK

  8. Impact of Intensive Therapy in Type 2 Diabetes Summary of Major Clinical Trials: BUT Subset Evaluations Show Reduced CV Outcomes if shorter duration of DM, without significant pre-existing complications Initial Trial Long Term Follow-up ↑- likely due to hypoglycemia and weight gain

  9. Meta-analysis of intensive glucose control in T2DM: major CV events including heart failure Numberofevents More intensive Less intensive Differencein HR(95%CI) HbA1c(%) -0.88 0.96 (0.83,1.10) Stroke 378 370 Myocardialinfarction 730 745 -0.88 0.85 (0.76,0.94) Hospitalisation for or death from heart failure 459 446 -0.88 1.00 (0.86,1.16) 0,50 1,00 2,00 Favoursmoreintensive Favourslessintensive • Meta-analysis of 27,049 participants and 2370 major vascular events from: – – – – ADVANCE UKPDS ACCORD VADT HR, hazard ratio; CV, cardiovascular Turnbull FM et al. Diabetologia 2009;52:2288–2298

  10. But Why was there an apparent increase in Mortality in ACCORD, lack of benefit in ADVANCE • Weight Gain • Hypoglycemia • ACCORD • recorded PRIOR history mild severe events- • NO DOCUMENTATION OF GLUCOSE AT TIME OF DEATH

More Related